Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein

Abstract

Primary cutaneous follicle center lymphoma (PCFCL) is an indolent variant of follicular lymphoma (FL) with limited information available on the genetic background of the disease. The genetic hallmark of nodal FL, the t(14;18) translocation, affecting the BCL2 gene, is rare in PCFCL. Loss of 1p36, the most common secondary chromosomal abnormality in nodal FL, has been recently reported in 16.7% of PCFCL cases. In order to further characterize PCFCL, 21 cases were analyzed using interphase fluorescence in situ hybridization with BCL2 break apart and 1p36/1q25 dual color probes. Sanger sequencing was used to investigate TNFRSF14 and EZH2 mutations and immunohistochemistry to assess BCL2, EZH2 protein expressions.

1p36 deletion occurred in 22% (5/21), BCL2 gene break in 10% (2/20) of the PCFCL cases. Mutations of the candidate tumor suppressor gene of the 1p36 region, TNFRSF14 mutations were detected in 4/17 (23.5%) cases with 2 cases presenting with concurrent 1p36 deletion. EZH2 hotspot mutations at Y641, A682, and A692 were not found. High EZH2 protein expression associated with a BCL2 negative phenotype was observed in 43% (9/21) of the cases. BCL2 gene break or 1p36 deletion did not impact the prognosis; however, they showed association with advanced stages at diagnosis (p = 0.016) and a tendency with shorter event free survival (p = 0.052).

In conclusion, 1p36 deletion co-occurs with acquired TNFRSF14 mutations, suggesting a role of this tumor suppressor gene in the development of a subgroup of PCFCL. High EZH2 protein expression associated with BCL2 negative phenotype is common and might represent an ideal therapeutic target.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, Diaz-Perez JL, Geerts ML, Goos M, Knobler R, Ralfkiaer E, Santucci M, Smith N, Wechsler J, van Vloten WA, Meijer CJ (1997) EORTC classification for primary cutaneous lymphomas: a proposal from the cutaneous lymphoma study Group of the European Organization for Research and Treatment of Cancer. Blood 90(1):354–371

  2. 2.

    Senff NJ, Hoefnagel JJ, Neelis KJ, Vermeer MH, Noordijk EM, Willemze R (2007) Results of radiotherapy in 153 primary cutaneous B-cell lymphomas classified according to the WHO-EORTC classification. Arch Dermatol 143(12):1520–1526. https://doi.org/10.1001/archderm.143.12.1520

  3. 3.

    Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105(10):3768–3785. https://doi.org/10.1182/blood-2004-09-3502

  4. 4.

    Goodlad JR, Krajewski AS, Batstone PJ, McKay P, White JM, Benton EC, Kavanagh GM, Lucraft HH (2002) Primary cutaneous follicular lymphoma: a clinicopathologic and molecular study of 16 cases in support of a distinct entity. Am J Surg Pathol 26(6):733–741. https://doi.org/10.1097/00000478-200206000-00006

  5. 5.

    Vergier B, Belaud-Rotureau MA, Benassy MN, Beylot-Barry M, Dubus P, Delaunay M, Garroste JC, Taine L, Merlio JP (2004) Neoplastic cells do not carry bcl2-JH rearrangements detected in a subset of primary cutaneous follicle center B-cell lymphomas. Am J Surg Pathol 28(6):748–755. https://doi.org/10.1097/01.pas.0000126775.27698.6e

  6. 6.

    Kim BK, Surti U, Pandya A, Cohen J, Rabkin MS, Swerdlow SH (2005) Clinicopathologic, immunophenotypic, and molecular cytogenetic fluorescence in situ hybridization analysis of primary and secondary cutaneous follicular lymphomas. Am J Surg Pathol 29(1):69–82. https://doi.org/10.1097/01.pas.0000146015.22624.c7

  7. 7.

    Streubel B, Scheucher B, Valencak J, Huber D, Petzelbauer P, Trautinger F, Weihsengruber F, Mannhalter C, Cerroni L, Chott A (2006) Molecular cytogenetic evidence of t(14;18)(IGH;BCL2) in a substantial proportion of primary cutaneous follicle center lymphomas. Am J Surg Pathol 30(4):529–536. https://doi.org/10.1097/00000478-200604000-00015

  8. 8.

    Abdul-Wahab A, Tang SY, Robson A, Morris S, Agar N, Wain EM, Child F, Scarisbrick J, Neat M, Whittaker S (2014) Chromosomal anomalies in primary cutaneous follicle center cell lymphoma do not portend a poor prognosis. J Am Acad Dermatol 70(6):1010–1020. https://doi.org/10.1016/j.jaad.2014.01.862

  9. 9.

    Lucioni M, Berti E, Arcaini L, Croci GA, Maffi A, Klersy C, Goteri G, Tomasini C, Quaglino P, Riboni R, Arra M, Dallera E, Grandi V, Alaibac M, Ramponi A, Rattotti S, Cabras MG, Franceschetti S, Fraternali-Orcioni G, Zerbinati N, Onida F, Ascani S, Fierro MT, Rupoli S, Gambacorta M, Zinzani PL, Pimpinelli N, Santucci M, Paulli M (2016) Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: comparison with current classification and definition of prognostic markers. Cancer Med 5(10):2740–2755. https://doi.org/10.1002/cam4.865

  10. 10.

    Verdanet E, Dereure O, Rene C, Tempier A, Benammar-Hafidi A, Gallo M, Frouin E, Durand L, Gazagne I, Costes-Martineau V, Cacheux V, Szablewski V (2017) Diagnostic value of STMN1, LMO2, HGAL, AID expression and 1p36 chromosomal abnormalities in primary cutaneous B cell lymphomas. Histopathology 71(4):648–660. https://doi.org/10.1111/his.13279

  11. 11.

    Launay E, Pangault C, Bertrand P, Jardin F, Lamy T, Tilly H, Tarte K, Bastard C, Fest T (2012) High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis. Leukemia 26(3):559–562. https://doi.org/10.1038/leu.2011.266

  12. 12.

    Bouska A, McKeithan TW, Deffenbacher KE, Lachel C, Wright GW, Iqbal J, Smith LM, Zhang W, Kucuk C, Rinaldi A, Bertoni F, Fitzgibbon J, Fu K, Weisenburger DD, Greiner TC, Dave BJ, Gascoyne RD, Rosenwald A, Ott G, Campo E, Rimsza LM, Delabie J, Jaffe ES, Braziel RM, Connors JM, Staudt LM, Chan WC (2014) Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood 123(11):1681–1690. https://doi.org/10.1182/blood-2013-05-500595

  13. 13.

    Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, Yap D, Humphries RK, Griffith OL, Shah S, Zhu H, Kimbara M, Shashkin P, Charlot JF, Tcherpakov M, Corbett R, Tam A, Varhol R, Smailus D, Moksa M, Zhao Y, Delaney A, Qian H, Birol I, Schein J, Moore R, Holt R, Horsman DE, Connors JM, Jones S, Aparicio S, Hirst M, Gascoyne RD, Marra MA (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42(2):181–185. https://doi.org/10.1038/ng.518

  14. 14.

    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (2017) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4h Edition, vol 2, 4th edn. IARC press, Lyon

  15. 15.

    Langerak AW, Groenen P, Brüggemann M, Beldjord K, Bellan C, Bonello L, Boone E, Carter GI, Catherwood M, Davi F, Delfau-Larue M, Diss T, Evans PAS, Gameiro P, Garcia Sanz R, Gonzalez D, Grand D, Håkansson Å, Hummel M, Liu H, Lombardia L, Macintyre EA, Milner BJ, Montes-Moreno S, Schuuring E, Spaargaren M, Hodges E, van Dongen JJM (2012) EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia 26(10):2159–2171. https://doi.org/10.1038/leu.2012.246

  16. 16.

    Papp G, Mihaly D, Sapi Z (2017) Unusual signal patterns of break-apart FISH probes used in the diagnosis of soft tissue sarcomas. Pathology oncology research : POR 23(4):863–871. https://doi.org/10.1007/s12253-017-0200-z

  17. 17.

    Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, Dummer R, Hoppe RT (2007) TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110(2):479–484. https://doi.org/10.1182/blood-2006-10-054601

  18. 18.

    Cheung KJ, Johnson NA, Affleck JG, Severson T, Steidl C, Ben-Neriah S, Schein J, Morin RD, Moore R, Shah SP, Qian H, Paul JE, Telenius A, Relander T, Lam W, Savage K, Connors JM, Brown C, Marra MA, Gascoyne RD, Horsman DE (2010) Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res 70(22):9166–9174. https://doi.org/10.1158/0008-5472.CAN-10-2460

  19. 19.

    Szablewski V, Ingen-Housz-Oro S, Baia M, Delfau-Larue MH, Copie-Bergman C, Ortonne N (2016) Primary cutaneous follicle center lymphomas expressing BCL2 protein frequently harbor BCL2 gene break and may present 1p36 deletion: a study of 20 cases. Am J Surg Pathol 40(1):127–136. https://doi.org/10.1097/pas.0000000000000567

  20. 20.

    Katzenberger T, Kalla J, Leich E, Stocklein H, Hartmann E, Barnickel S, Wessendorf S, Ott MM, Muller-Hermelink HK, Rosenwald A, Ott G (2009) A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood 113(5):1053–1061. https://doi.org/10.1182/blood-2008-07-168682

  21. 21.

    Schmidt J, Gong S, Marafioti T, Mankel B, Gonzalez-Farre B, Balague O, Mozos A, Cabecadas J, van der Walt J, Hoehn D, Rosenwald A, Ott G, Dojcinov S, Egan C, Nadeu F, Ramis-Zaldivar JE, Clot G, Barcena C, Perez-Alonso V, Endris V, Penzel R, Lome-Maldonado C, Bonzheim I, Fend F, Campo E, Jaffe ES, Salaverria I, Quintanilla-Martinez L (2016) Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood 128(8):1101–1111. https://doi.org/10.1182/blood-2016-03-703819

  22. 22.

    Pham-Ledard A, Cowppli-Bony A, Doussau A, Prochazkova-Carlotti M, Laharanne E, Jouary T, Belaud-Rotureau MA, Vergier B, Merlio JP, Beylot-Barry M (2015) Diagnostic and prognostic value of BCL2 rearrangement in 53 patients with follicular lymphoma presenting as primary skin lesions. Am J Clin Pathol 143(3):362–373. https://doi.org/10.1309/ajcp4subr4npsptn

  23. 23.

    Lawnicki LC, Weisenburger DD, Aoun P, Chan WC, Wickert RS, Greiner TC (2002) The t(14;18) and bcl-2 expression are present in a subset of primary cutaneous follicular lymphoma: association with lower grade. Am J Clin Pathol 118(5):765–772. https://doi.org/10.1309/2tju-dnlq-5jba-ab4t

  24. 24.

    Costello RT, Mallet F, Barbarat B, Schiano De Colella JM, Sainty D, Sweet RW, Truneh A, Olive D (2003) Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity. Leukemia 17(12):2500–2507. https://doi.org/10.1038/sj.leu.2403175

  25. 25.

    Harrop JA, McDonnell PC, Brigham-Burke M, Lyn SD, Minton J, Tan KB, Dede K, Spampanato J, Silverman C, Hensley P, DiPrinzio R, Emery JG, Deen K, Eichman C, Chabot-Fletcher M, Truneh A, Young PR (1998) Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem 273(42):27548–27556. https://doi.org/10.1074/jbc.273.42.27548

  26. 26.

    van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP, Meijer CJ (2001) Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97(12):3896–3901. https://doi.org/10.1182/blood.V97.12.3896

  27. 27.

    Zhou Z, Gao J, Popovic R, Wolniak K, Parimi V, Winter JN, Licht JD, Chen YH (2015) Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation. Leuk Lymphoma 56(10):2895–2901. https://doi.org/10.3109/10428194.2015.1006220

  28. 28.

    Shi M, Shahsafaei A, Liu C, Yu H, Dorfman DM (2015) Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases. Leuk Lymphoma 56(7):2087–2091. https://doi.org/10.3109/10428194.2014.968780

  29. 29.

    Lee HJ, Shin DH, Kim KB, Shin N, Park WY, Lee JH, Choi KU, Kim JY, Lee CH, Sol MY (2014) Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma 55(9):2056–2063. https://doi.org/10.3109/10428194.2013.858816

Download references

Acknowledgements

This work was funded by the Momentum grant (LP-95021) of the Hungarian Academy of Sciences and the NVKP_16-1-2016-0004 and KH17-126718 grants of the Hungarian National Research, Development and Innovation Office (NKFIH).

Funding

This work was funded by the Momentum grant (LP-95021) of the Hungarian Academy of Sciences and the NVKP_16-1-2016-0004 KH17-126718 grants of the Hungarian National Research, Development and Innovation Office (NKFIH).

Author information

MM, EK, TS, and MV have made substantial contributions to acquisition of the data. AG, BB, MV, DK, GP, and JC have made substantial contributions to analysis and interpretation of data. ÁSZ, CB, and AM made substantial contribution to conception and design of the manuscript, and ÁSZ has written the manuscript. AG, BB, MV, DK, GP, JC, and CB conducted cytogenetic, phenotypic, and biologic analyses. All authors have been involved in revising the manuscript and approved the final manuscript.

Correspondence to Ágota Szepesi.

Ethics declarations

All protocols were approved by the Institutional Ethical Review Board (TUKEB no. 7/2006).

Conflicts of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

ESM 1

(DOCX 32 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gángó, A., Bátai, B., Varga, M. et al. Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein. Virchows Arch 473, 453–462 (2018). https://doi.org/10.1007/s00428-018-2384-3

Download citation

Keywords

  • Primary cutaneous follicle center lymphoma
  • del 1p36
  • TNFRSF14 mutation
  • BCL2
  • EZH2